159 results about "Pharmaceutical Dose Form" patented technology

Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt a pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Methods and apparatus (10) for Raman spectral analysis of a sample (12), such as a pharmaceutical dosage form, are disclosed. Delivery optics (16) are used to deliver probe light to a delivery region (13) on the sample, and collection optics (20) are used to collect, from a collection region (17) on the sample spaced from the delivery region, the probe light following scattering through the sample. Each of a plurality of target Raman spectral features are measured in the collected light, and a spectral distortion of the collected light arising during scattering through the sample is determined. A property of the sample is then quantified using the target Raman spectral features in combination with the determined spectral distortion, such that the quantified property is compensated for the spectral distortion.

A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of: neurological or psychiatric disease or condition.

The present invention relates to the field of medicine and of dietary supplements, in particular the technical (i.e. medical-pharmaceutical or food-technology) field of sleep problems and sleep disorders. In particular, the present invention relates to a dosage form, in particular a dietary-supplement dosage form or pharmaceutical dosage form, in particular for oral administration, preferably for promoting or supporting sleep health or sleep behavior or preferably for use in the prophylactic or therapeutic treatment of sleep disorders or dysregulation of the natural day / night rhythm or the circadian rhythm.

The present invention discloses a cyclopeptide glass and a pharmaceutical composition glass containing a cyclopeptide. The cyclopeptide glass of the present invention can simultaneously exert efficacy and function as a drug adjuvant. Compared with crystals and traditional drug dosage forms or adjuvants, the cyclopeptide glass effectively increases a drug dissolution rate, improves drug bioavailability, and may be widely used in the fields of drug delivery and sustained release for resistance to tumors, resistance to viruses / bacteria, blood sugar control, immune regulation, neuromodulation, etc.

There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and / or a volume-based mean diameter, and / or a structural / particle density, that is / are similar to the weight- and / or volume-based mean diameter, and / or the structural / particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and / or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

The invention discloses a yunaconitine derivative and application of the yunaconitine derivative in preparation of hypoglycemic and antioxidant drugs, the yunaconitine derivative has a chemical structure as shown in a formula 1a or 1b, and the invention further provides application of the yunaconitine derivative in preparation of PTP1B inhibitors. The dosage form of the medicine is selected from at least one of a tablet, a capsule, a granule, a dripping pill, a suspension, syrup, an enteric-coated preparation, an emulsion suspension and an injection. The yunaconitine derivative disclosed by the invention is high in bioavailability and clinical use value, provides a candidate lead compound for research and development of novel preparations of hypoglycemic and antioxidant drugs, and has potential application value in the fields of hypoglycemic and antioxidant targeted drugs, probe design and fluorescent biomarkers.

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.

The present invention refers to a liquid pharmaceutical Cetrorelix composition comprising a stabilizing agent selected from poloxamer having an t average molecular weight of 7,000-12,000 g / mol and / or benzyl alcohol, a pharmaceutical dosage form comprising said liquid pharmaceutical composition, and their use in inhibiting premature luteinizing hormone surges in woman undergoing controlled ovarian stimulation. Further, a method for preparing the liquid pharmaceutical Cetrorelix composition and pharmaceutical dosage form is disclosed.

An oral pharmaceutical dosage form, which is intended to provide the desired retention in an individual on the basis of geometric differences between dosage form states before and after administration. The oral pharmaceutical dosage form comprises swellable and expandable material (5). The material (5), upon swelling or expansion, drives the overall size of the oral pharmaceutical dosage form to expand, thereby allowing the oral pharmaceutical dosage form to remain in the stomach for a desired period of time.

The present invention relates to a pharmaceutical dosage form for application to a mucous membrane, in particular to a buccal, intestinal, rectal or vaginal mucous membrane, comprising at least one sheet like, in particular film shaped, foil shaped or wafer shaped preparation comprising the active pharmaceutical ingredient, a release mechanism, and a trigger mechanism, wherein the trigger mechanism is adapted to trigger, at a predetermined site of action, in particular of the gastrointestinal tract, of the rectum or of the vagina, the release of the sheet like preparation by the release mechanism.

ZnCl2 co-crystal of racemic-(±)-blarcamesine hydrochloride of formula 2a, ZnCl2 co-crystal of (S)-(−)-blarcamesine hydrochloride of formula 2b and ZnCl2 co-crystal of (R)-(+)-blarcamesine hydrochloride of formula 2c, processes for preparation thereof and pharmaceutical preparation thereof and methods of treating neurodegenerative, neurodevelopmental diseases such as Alzheimer's disease, Parkinson's disease dementia and / or Rett syndrome.

The invention belongs to the technical field of medicine dosage forms, and particularly relates to a conjugated estrogen-progestational hormone double-layer tablet and a preparation method thereof. The preparation method comprises the following steps: performing powder mixing on conjugated estrogen and a first medicine auxiliary material to obtain conjugated estrogen powder; carrying out wet granulation on progestational hormone and a second medicine auxiliary material to obtain progestational hormone granules; and tabletting the conjugated estrogen powder and the progestational hormone particles by using a double-layer tablet press to obtain the conjugated estrogen-progestational hormone double-layer tablet. The conjugated estrogen-progestational hormone double-layer tablet prepared by the invention can simultaneously meet the slow release of conjugated estrogen and the quick release of progestational hormone, so that the medicine taking frequency is reduced, and the compliance of a patient is improved; and meanwhile, the stability of a drug bound with estrogen and the bioavailability of progestational hormone are improved.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and chidaridine.

Recently, we have introduced 3D-micro-patterned pharmaceutical dosage forms for enhancing the efficacy, safety, convenience, and cost-effectiveness of drug therapies. Presented herein is an apparatus for the manufacture of such dosage forms. The apparatus comprises at least a first extruder and at least a second extruder. The first extruder comprises an extruder channel having an exit port with a valve mated to an input port of a second extruder. Said second extruder comprises a translatable piston for extruding plasticized fiber at controlled speed. The apparatus further comprises a stage movable at the controlled speed of the extruded fiber for depositing said fiber to a three dimensional structural framework.

The present application provides a kind of nintedanib solution for inhalation and preparation method and application, the inhalation solution includes active substance, solvent and auxiliary material, the single dose specification of the inhalation solution is 1-5ml, and the active substance in single dose specification is 2.41-12.04mg / ml nintedanib ethanesulfonic acid;The solvent is sterile injection solution water;The auxiliary material includes isotonicity regulator and pH regulator and can also include antioxidant;The addition amount of the isotonicity regulator is to make the inhalation solution have the weight molal osmotic concentration of 240-400mOsmol / kg;The addition of the pH regulator is to make the pH value of the inhalation solution preparation 3.0-4.0.The inhalation nintedanib solution of the present application can provide a kind of nintedanib for inhalation with convenient, safe and effective, and good stability of drug dosage form and drug delivery system in combination with liquid atomization device.

The present invention relates to a pharmaceutical dosage form for application to a mucous membrane, in particular to a buccal, intestinal, rectal or vaginal mucous membrane, comprising at least one string-like or strip-like preparation comprising the active pharmaceutical ingredient, the dosage from consisting a first and a second halve-capsule shell, which jointly define the size of an aperture for releasing the preparation. The invention also relates to a method of producing the pharmaceutical dosage form.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

To provide a method and system of forming a pharmaceutical dosage form within a portion of a blister packaging 1.SOLUTION: The method includes a step of providing a blister packaging for the dosage form with depressions 4. A predetermined amount of a drug-containing powder material comprising drug-containing particles is deposited into a substantially uniform powder layer within the depressions 4. A binding liquid is then deposited in a pattern on the powder layer within the depressions 4, to bind the particles of the powder layer and form an incremental wetted layer. Excess solvent in the binding material can be removed to form an incremental bound layer. These steps are repeated in sequence at least one or more times to form the pharmaceutical dosage form within the blister packaging 1.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of biological medicines, and particularly relates to application of an ITGA6 inhibitor in preparation of a medicine for treating uveal melanoma. By integrating bioinformatics analysis of databases of TCGA, GTEx, CPTAC and the like, the invention systematically reveals that the ITGA6 has high specific expression in uveal melanoma and is significantly related to poor prognosis of a patient for the first time. In-vitro experiments prove that by knocking down ITGA6, proliferation, migration, invasion and colony forming ability of UVM cells can be effectively inhibited. According to the invention, small molecular compounds such as 4.5-diphenyl-1H-imidazole, MS-275, W-13 and the like and siRNA (small interfering Ribonucleic Acid) targeting ITGA6 are screened out to be used as effective inhibitors, and specific drug dosage forms such as intraocular injection and the like are provided. In addition, the ITGA6 inhibitor can be used in combination with a PD-1 / PD-L1 inhibitor, a CTLA-4 inhibitor or a chemotherapeutic drug to generate a synergistic anti-tumor effect. Mechanism research shows that ITGA6 promotes UVM progress by regulating a signal channel and a tumor immune microenvironment. The invention provides a new targeted treatment strategy for uveal melanoma, and has important clinical application value.

The present invention relates to a solid pharmaceutical dosage form for oral administration, comprising (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32, 5-dioxo-14-(trifluoromethyl)-32H-6-aza-3 (4, 1)-pyridine-1 (1)-[1, 2, 3] triazole-2 (1, 2), 7 (1)-dibenzaheptaphane-74-carboxamide (active ingredient (I)), and a pharmaceutically acceptable salt thereof. The active ingredient (I) is present in amorphous form and is released immediately from a solid pharmaceutical dosage form for oral administration, and to a method for the production thereof, to the use thereof as a medicament, and to the use thereof for the treatment and / or prophylaxis of diseases, in particular diseases, such as diseases. Use in particular for cardiovascular disorders, preferably thrombotic or thromboembolic disorders and oedema and ocular disorders

The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising(i) levodopa in an amount ranging from 50 mg to 300 mg,(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically equivalent amount of another aromatic amino acid decarboxylase inhibitor, and(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the proportion of entacapone to carbidopa in said dosage form ranges from 0.3:1.0 to 3.2:1.0 by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight. Pharmaceutical dosage form used in said method are also disclosed.

This invention relates to solid state forms of Rencofilstat (RCF), pharmaceutical compositions comprising the same, and methods of manufacturing pharmaceutical dosage forms utilizing the same.

The present disclosure generally relates to the use of polyvinyl alcohol (PVA) in additive manufacturing technologies and techniques. More specifically, the present disclosure relates to the use of PVA in a selective laser sintering (SLS) method to additively manufacture an object, in particular a pharmaceutical dosage form.

To provide a system and device for additive manufacturing, as well as method of using the device.SOLUTION: A device and system are provided for depositing a material or producing a product, such as pharmaceutical dosage form, by additive manufacturing. Additionally, a method of using the device and system, as well as method of producing the product such as pharmaceutical dosage form by additive manufacturing, are provided. In certain embodiments, the device includes a material supply system configured to melt and pressurize the material, a pressure sensor (214) configured to detect a pressure of the material within the device, and a control switch (216) including a sealing needle (218) operable in open and closed positions.SELECTED DRAWING: Figure 2A

The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof that inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Sustained-release oral pharmaceutical compositions comprising the pharmaceutical composition are described, as well as sustained-release injectable pharmaceutical compositions comprising the pharmaceutical composition.The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal administration comprising the pharmaceutical composition. Also described are: methods for evaluating the efficacy of the pharmaceutical composition; methods for evaluating the inhibitory or partial inhibitory activity of the pharmaceutical composition; methods for treating, alleviating, or preventing a condition or disease comprising administering a therapeutically effective amount of the pharmaceutical composition to a subject; and the use of the pharmaceutical composition for manufacturing a pharmaceutical dosage form for the treatment of a disease.

The present invention provides a kind of favipiravir solution for atomized inhalation, preparation method and application. The inhalation solution contains 1-50mg / ml favipiravir, excipients and solvent in a single dose, and the pH value is 5.5-9.0, and the inhalation solution single dose specification is 2-5ml. The excipients include a cosolvent, a pH regulator and an osmotic pressure regulator. The cosolvent is selected from meglumine, and the mass ratio of favipiravir to meglumine is 1:1.25-1:1.34, and the pH regulator can be selected from sodium dihydrogen phosphate, disodium hydrogen phosphate, and one or more of potassium dihydrogen phosphate, the osmotic pressure regulator is selected from sodium chloride, and the solvent is selected from sterile water for injection. The solution of favipiravir can be used in combination with a liquid atomizer to provide a convenient, safe, effective and stable pharmaceutical dosage form and drug delivery system of favipiravir.